Alkermes

In News

Alkermes plans label expansion for Avadel-acquired narcolepsy drug - FirstWord Pharma

FirstWord Pharma - May 12, 2026

Alkermes Sees Upside To Its Avadel Buy With Phase III Lumryz Win In IH - Citeline News & Insights

Citeline News & Insights - May 12, 2026

Alkermes’ Lumryz hits phase 3 mark in another sleep disorder, fueling momentum from $2.4B Avadel acquisition - Fierce Pharma

Fierce Pharma - May 12, 2026

Alkermes’ narcolepsy Phase 3 success; Boehringer’s antibody deal - Endpoints News

Endpoints News - May 12, 2026

Alkermes' (NASDAQ:ALKS) Conservative Accounting Might Explain Soft Earnings - simplywall.st

simplywall.st - May 12, 2026

Alkermes stock maintains Buy rating on positive sleep disorder trial - Investing.com

Investing.com - May 12, 2026

Alkermes posts late-stage trial win for Lumryz in new sleep disorder - Seeking Alpha

Seeking Alpha - May 12, 2026

Alkermes Announces Positive Phase 3 REVITALYZ Results for LUMRYZ, Plans sNDA Filing by End of 2026 - TradingView

TradingView - May 12, 2026

Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia - Yahoo Finance

Yahoo Finance - May 12, 2026

Alkermes Earnings Surprise Keeps Nasdaq Composite Watching - Kalkine Media

Kalkine Media - May 12, 2026

Alkermes (Nasdaq: ALKS) reports strong phase 3 LUMRYZ results in idiopathic hypersomnia - Stock Titan

Stock Titan - May 12, 2026

Alkermes Reports Positive Phase 3 Results for LUMRYZ - TipRanks

TipRanks - May 12, 2026

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment